Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis.
作者信息
Gandhi Shiv, Zelman Sara, De Armas Ricardo Eduardo, Hemond Christopher, Levy Alexander N, Singh Siddharth, Korzenik Joshua, Jangi Sushrut
机构信息
Division of Gastroenterology, Tufts Medical Center, Boston, MA, United States.
Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, United States.
出版信息
Inflamm Bowel Dis. 2022 Oct 3;28(10):1614-1617. doi: 10.1093/ibd/izac053.
Abstract
摘要
相似文献
1
Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis.多发性硬化症患者中新发炎症性肠病的自然病史。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1614-1617. doi: 10.1093/ibd/izac053.
2
Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.炎症性肠病患者的狭窄和瘘管形成克罗恩病与抗肿瘤坏死因子诱导的银屑病有关。
Dig Dis Sci. 2018 Sep;63(9):2430-2438. doi: 10.1007/s10620-018-5096-2. Epub 2018 May 8.
3
Increased risk for demyelinating diseases in patients with inflammatory bowel disease.炎症性肠病患者患脱髓鞘疾病的风险增加。
Gastroenterology. 2005 Sep;129(3):819-26. doi: 10.1053/j.gastro.2005.06.022.
4
[The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].[生物疗法在炎症性肠病肠外表现及并发症治疗中的作用]
Acta Med Croatica. 2013 Apr;67(2):195-201.
5
Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.接受抗肿瘤坏死因子α制剂治疗的炎症性肠病儿科患者中的银屑病和银屑病样皮疹
Pediatr Dermatol. 2017 May;34(3):253-260. doi: 10.1111/pde.13081. Epub 2017 Feb 17.
6
Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.多发性硬化症与炎症性肠病：一项系统评价与荟萃分析
J Neurol. 2017 Feb;264(2):254-259. doi: 10.1007/s00415-016-8340-8. Epub 2016 Nov 22.
7
Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease.炎症性肠病患者中与肿瘤坏死因子拮抗剂相关或不相关的视神经炎
J Crohns Colitis. 2016 May;10(5):541-8. doi: 10.1093/ecco-jcc/jjw003. Epub 2016 Jan 12.
8
Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.炎症性肠病在治疗炎症性风湿性疾病的抗 TNF-α 治疗期间的发展：全国系列研究。
Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.
9
The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.抗 TNF 治疗对炎症性肠病患者慢性丙型肝炎病毒感染病程的影响。
Dig Dis Sci. 2013 Apr;58(4):1149-56. doi: 10.1007/s10620-012-2457-0. Epub 2012 Nov 20.
10
Progression to Anti-TNF Treatment in Very Early Onset Inflammatory Bowel Disease Patients.早期发病炎症性肠病患者的抗 TNF 治疗进展。
J Pediatr Gastroenterol Nutr. 2022 Oct 1;75(4):473-479. doi: 10.1097/MPG.0000000000003551. Epub 2022 Jul 11.
引用本文的文献
1
Inflammatory Bowel Disease and Neurodegenerative Diseases.炎症性肠病与神经退行性疾病。
Gut Liver. 2023 Jul 15;17(4):495-504. doi: 10.5009/gnl220523. Epub 2023 Feb 27.
本文引用的文献
1
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.奥扎莫德治疗中重度活动性溃疡性结肠炎的长期疗效和安全性：随机、 2 期 TOUCHSTONE 研究开放性扩展的结果。
J Crohns Colitis. 2021 Jul 5;15(7):1120-1129. doi: 10.1093/ecco-jcc/jjab012.
2
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.奥扎莫德与干扰素β-1a 在复发型多发性硬化症中的安全性和疗效（SUNBEAM）：一项多中心、随机、至少 12 个月、3 期临床试验。
Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.
3
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.接受司库奇尤单抗治疗的银屑病、银屑病关节炎和强直性脊柱炎患者中炎症性肠病的发生率：21 项临床试验汇总数据的回顾性分析。
Ann Rheum Dis. 2019 Apr;78(4):473-479. doi: 10.1136/annrheumdis-2018-214273. Epub 2019 Jan 23.
4
Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.
Mult Scler. 2014 Jul;20(8):1135-9. doi: 10.1177/1352458513515081. Epub 2013 Dec 10.
5
Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics.炎症性肠病患者的神经系统并发症：生物制剂时代日益增加的相关性。
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):864-72. doi: 10.1002/ibd.23011.
6
New IBD genetics: common pathways with other diseases.新的 IBD 遗传学：与其他疾病的共同途径。
Gut. 2011 Dec;60(12):1739-53. doi: 10.1136/gut.2009.199679. Epub 2011 Feb 7.
7
The comeback kid: TYSABRI now FDA approved for Crohn disease.东山再起者：泰萨比（TYSABRI）现已获美国食品药品监督管理局批准用于治疗克罗恩病。
J Clin Invest. 2008 Mar;118(3):825-6. doi: 10.1172/JCI35179.
8
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.使用英夫利昔单抗进行抗肿瘤坏死因子α治疗克罗恩病期间的脱髓鞘病变。
Inflamm Bowel Dis. 2004 Jan;10(1):28-31. doi: 10.1097/00054725-200401000-00004.
Zotero 插件